Iman Seyhoun

Iman Seyhoun


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2021 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
MSMahshid Saleh
Mahshid Saleh
AVAmir Abbas Vaezi
Amir Abbas Vaezi
RARasoul Aliannejad
Rasoul Aliannejad
ASAmir Ali Sohrabpour
Amir Ali Sohrabpour
SKSeyedeh Zahra Fotook Kiaei
Seyedeh Zahra Fotook Kiaei
JVJavad Verdi
Javad Verdi
Background: Mesenchymal stem cells (MSCs) have received particular attention because of their ability to modulate the immune system and inhibit inflammation caused by cytokine storms due to SARS-CoV-2. New alternative therapies may reduce mortality rates in patients with COVID19. This study aimed to assess the safety and efficacy of injecting intravenous Wharton’s jelly-derived MSCs in patients with COVID-19 as a treatment. Methods: In this study, five patients with severe COVID-19 were treated with Wharton’s jelly-derived mesenchymal stem cells (150 × 106 cells per injection). These patients were subject to three intravenous injections 3 days apart, and monitoring was done on days 0, 3, 6, and 14 in routine tests, inflammatory cytokines, and flow cytometry of CD4 and CD8 markers. A lung CT scan was performed on base and days 14 and 28. In addition, IgM and IgG antibodies against SARS-CoV-2 were measured before and after treatment. Results: The results showed that IL-10 and SDF-1 increased after cell therapy, but VEGF, TGF-β, IFN-γ, IL-6, and TNFα decreased. Routine hematology tests, myocardial enzyme tests, biochemical tests, and inflammation tests were performed for all patients before and after cell therapy on base and days 3, 6, and 14, which indicated the improvement of test results over time. COVID-19 antibody tests rose in 14 days after WJ-MSC injection. The total score of zonal involvement in both lungs was improved. Conclusions: In patients, the trend of tests was generally improving, and we experienced a reduction in inflammation. No serious complications were observed in patients except the headache in one of them, which was resolved without medication. In this study, we found that patients with severe COVID-19 in the inflammatory phase respond better to cell therapy. More extensive clinical trials should be performed in this regard. Trial registration: IRCT, IRCT20190717044241N2. Registered April 22, 2020.

10 September 2018 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
FHFaezeh Hosseinzadeh
Faezeh Hosseinzadeh
JVJavad Verdi
Javad Verdi
JAJafar Ai
Jafar Ai
SHSaieh Hajighasemlou
Saieh Hajighasemlou
ISIman Seyhoun
Iman Seyhoun
SSSadegh Shirian
Sadegh Shirian
High prevalence of hepatocellular carcinoma (HCC) and typically poor prognosis of this disease that lead to late stage diagnosis when potentially curative therapies are least effective; therefore, development of an effective and systematic treatment is an urgent requirement. In this review, several current treatments for HCC patients and their advantages or disadvantages were summarized. Moreover, various recent preclinical and clinical studies about the performances of “two efficient agents, sorafenib or natural killer (NK) cells”, against HCC cells were investigated. In addition, the focus this review was on the chemo-immunotherapy approach, correlation between sorafenib and NK cells and their effects on the performance of each other for better suppression of HCC. It was concluded that combinational therapy with sorafenib and NK cells might improve the outcome of applied therapeutic approaches for HCC patients. Finally, it was also concluded that interaction between sorafenib and NK cells is dose and time dependent, therefore, a careful dose and time optimizing is necessary for development of a combinational immune-cell therapy.

16 July 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
STShirin Tavakoli
Shirin Tavakoli
MSMaryam Samareh-Salavati
Maryam Samareh-Salavati
MRMahshid Akhavan Rahnama
Mahshid Akhavan Rahnama
SAShahrokh Abdolahi
Shahrokh Abdolahi
AHAli Hassanzadeh
Ali Hassanzadeh
MAMohammad Ahmadvand
Mohammad Ahmadvand
Hepatocellular carcinoma remains a major healthcare burden worldwide and is predicted to be the cause of death of 1.3 million people in 2040. Most HCC patients are diagnosed in advanced stages, leading to a poor prognosis. The development of targeted immunotherapies is essential to address this unmet clinical challenge. Natural killer (NK) cells have emerged as a promising cell-based therapeutic approach for treating solid tumors. NK cells have the distinctive ability to identify and destroy cancer cells without requiring prior sensitization. Here, we discuss potential approaches, developing strategies, and current challenges of NK cell therapy reported completely. In addition, advancements in immunotherapy, including adoptive NK cell therapy, and the strategies to boost NK cell function against HCC such as cytokine-based treatments, immune checkpoint inhibitors, vaccine-based approaches, genetic delivery, non-coding RNAs, antibody-based methods, and natural agents have been discussed. This comprehensive study provides a unique perspective by integrating recent findings on the differential impact of NK cells on HCC. We highlight the latest advances in NK cell engineering and immune checkpoint modulation, presenting a comparative analysis of therapeutic strategies. Furthermore, we critically assess the translational challenges associated with NK cell-based therapies, particularly focusing on their limited in vivo persistence and tumor immune evasion strategies.

9 February 2025 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
MSMaryam Samareh Salavatipour
Maryam Samareh Salavatipour
STShirin Tavakoli
Shirin Tavakoli
MBMaryam Barkhordar
Maryam Barkhordar
ISIman Seyhoun
Iman Seyhoun
NVNasim Vousooghi
Nasim Vousooghi
MAMohammad Ahmadvand
Mohammad Ahmadvand
Purpose: Blocking of inhibitory receptors such as NK group-2 member-A (NKG2A) enhances tumor immunity of natural killer (NK) cells. Additionally, antibody-dependent cellular cytotoxicity (ADCC) is an important cytotoxic modality of action of NK cells, which act as a functional bridge between innate and adaptive immunity. Here, we investigated the safety and feasibility of anti-NKG2A antibody-pretreated NK cells combined with IgG1 antibody (cetuximab) in patients with advanced gastric adenocarcinoma (GAC). Method: In this pilot study, treatment was initiated with cetuximab-based chemotherapy, followed by three times adoptive administration of anti-NKG2A pretreated NK cells (at doses 7×108 cells/injection) at 5-day intervals in three unresectable and locally advanced GAC patients who enrolled regarding vital signs and clinical characteristics. The clinical signs, laboratory parameters, and CTCAE (Common Terminology Criteria for Adverse Events) were documented for a safety and feasibility assessment. Results: The expanded cells were confirmed to be enriched in NK cells with high expression of CD56 (88.1%) and low expression of NKG2A (0.22%). The combination NK cell therapy was well tolerated, with transient adverse events. All patients were alive at the last follow-up (24 weeks). All patients showed overall decreases in tumor size and CA 19–9 level 4 weeks after combination therapy. However, two patients showed progressive disease (PD) after 12 weeks and the level of CA19-9 was increased in all three patients after 24 weeks. Conclusion: In conclusion, this study demonstrated the safety and feasibility of infusing high doses of anti-NKG2A pretreated NK cells combined with cetuximab in patients with GAC.

24 August 2026 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
HGHediye Gholamshahi
Hediye Gholamshahi
MDMohammad Mahdi Dehnavi
Mohammad Mahdi Dehnavi
FCFatemeh Chinisaz
Fatemeh Chinisaz
AAAzadeh Aletaha
Azadeh Aletaha
ISIman Seyhoun
Iman Seyhoun
MZMasoumeh Majidi Zolbin
Masoumeh Majidi Zolbin
Premature ovarian insufficiency (POI) is a multifactorial disorder marked by the cessation of ovarian function prior to the age of 40. While its genetic an

7 November 2026 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
AEasrin emami
asrin emami
FAFatemeh Ashrafi
Fatemeh Ashrafi
MRMaryam Rahnama
Maryam Rahnama
MSMetanat Safari
Metanat Safari
IOIman Menbari Oskouie
Iman Menbari Oskouie
AJArsalan Jalili
Arsalan Jalili
Background: Exosome/small extracellular vesicle (sEV)-functionalized scaffolds represent a promising cell-free strategy for bone regeneration by combining biomaterial structural support with sustained EV-mediated osteogenic, angiogenic, and immunomodulatory signaling. Methods: A PRISMA 2020–compliant systematic review and meta-analysis was conducted, prospectively registered in the PROSPERO database (registration number: CRD420251248297), to synthesize preclinical evidence from animal bone defect models and complementary in vitro studies published between January 1, 2010, and August 28, 2025. PubMed/MEDLINE, Scopus, Web of Science Core Collection, Embase, and Google Scholar were searched for English-language preclinical studies evaluating EV/sEV-functionalized scaffolds, including studies describing these vesicle preparations as exosomes. Animal bone defect models were considered for quantitative synthesis, while in vitro studies provided complementary mechanistic evidence. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the SYRCLE tool. Random-effects meta-analyses pooled standardized week-8 outcomes as Hedges’ g. Results: Forty-one studies were included in the qualitative synthesis and 24 were eligible for the meta-analysis. Most investigations combined in vitro and in vivo experiments, were conducted in China, and used rat models, particularly critical-sized calvarial defects. Mesenchymal stem cell-derived exosome/sEV preparations, frequently described as exosomes by the original studies, predominated, particularly those derived from bone marrow MSCs. Physical adsorption and hydrogel encapsulation were the most commonly reported incorporation strategies. At week 8, exosome/sEV-functionalized scaffolds significantly improved bone volume fraction (BV/TV; 17 studies; standardized mean difference (SMD) [Hedges’ g]=6.00, 95% CI 4.19–7.81) and bone mineral density (BMD; 7 studies; Hedges’ g=5.27, 95% CI 2.95–7.60), although substantial heterogeneity remained. Conclusion: Exosome/sEV-functionalized scaffolds were associated with improvements in quantitative radiological outcomes, with complementary qualitative evidence from histological assessments. However, interpretation of these findings is limited by methodological variability and heterogeneity among preclinical studies. Standardized reporting, improved randomization/blinding, and large-animal validation are needed to refine effect estimates before clinical translation.